The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
该披露涉及化合物的晶体形式,其
化学式为:
化学式(I),以及其药用可接受的盐。还描述了包含化合物I的药物组合物,以及其使用和制备方法。